



Pediatric Atopic Dermatitis: Clinical Scenarios

Clinical Brief #2 – Adolescents with Moderate to Severe AD

References

Tweet 2 References:

Chernyshov PV. Stigmatization and self-perception in children with atopic dermatitis. *Clin Cosmet Investig Dermatol*. 2016;9:159-166.

Erdogan Y, Erturan I, Aktepe E, Akyildiz A. Comparison of quality of life, depression, anxiety, suicide, social anxiety and obsessive-compulsive symptoms between adolescents with acne receiving isotretinoin and antibiotics: a prospective, non-randomised, open-label study. *Pediatr Drugs*. 2019;21:195-202.

Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. *Lancet*. 2021;397:2151-2168.

Kelly KA, Balogh EA, Kaplan SG, Feldman SR. Skin disease in children: effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients. *Children (Basel)*. 2021;8:1057.

Lee DG, Gui XY, Mukovozov I, Fleming P, Lynde C. Sleep disturbances in children with atopic dermatitis: a scoping review. *J Cutan Med Surg*. 2023;27:157-164.

Manjunath J, Silverberg NB, Silverberg JI. Association of atopic dermatitis with poor school behaviours in US children and adolescents. *J Eur Acad Dermatol Venereol*. 2022;36:e346-e348.

Manjunath J, Silverberg JI. Atopic dermatitis is associated with multiple behavioral problems in us children and adolescents. *Dermatitis*. 2022;33:S52-S60.

Paller AS, Beck LA, Blauvelt A, et al. Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data. *Pediatr Dermatol*. 2022;39:187-196.

Su W, Chen H, Gao Y, et al. Anxiety, depression and associated factors among caretakers of children with atopic dermatitis. *Ann Gen Psychiatry*. 2022;21:12.

Wan J, Mitra PD, Hooper Sr, Hoffstad OJ, Margolis DJ. Association of atopic dermatitis severity with learning disability in children. *JAMA Dermatol*. 2021;157:1-7.



Additional References:

Barbarot S, Silverberg JI, Gadkari A, et al. The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study. *J Pediatr*. 2022;246:220-226.

Chernyshov PV. Stigmatization and self-perception in children with atopic dermatitis. *Clin Cosmet Investig Dermatol*. 2016;9:159-166.

Manjunath J, Silverberg NB, Silverberg JI. Association of atopic dermatitis with delinquent behaviors in US children and adolescents. *Arch Dermatol Res*. 2022;314:975-982.

Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. *J Am Acad Dermatol*. 2020;83:1282-1293.

Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2022;400:908-919.

Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. *JAMA Dermatol*. 2020;156:44-56.

Glossary

AD, atopic dermatitis

EASI-75, Eczema Area and Severity Index $\geq 75\%$ improvement

JAK, Janus kinase

vIGA-AD, validated Investigator's Global Assessment for Atopic Dermatitis

w/, with